Market Overview

UPDATE: Dawson James Initiates Pharmacyclics at Market Outperform on Ibrutinib Confidence

Related PCYC
Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma
AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematologic Cancers

Dawson James initiated coverage on Pharmacyclics (NASDAQ: PCYC) with a Market Outperform rating and a $101 price target.

Dawson James commented, "Ibrutinib – a novel Btk inhibitor - represents the most exciting compound in the field of the multi-billion dollar market for B-cell related malignancies. Ibrutinib is, by far, the leader in this therapeutic category, easily has blockbuster potential and, based upon our analysis, is likely to elevate PCYC valuation to the very top-tier of biotech stocks. We believe the upcoming American Society Hematology meeting (ASH, December 7-12, Atlanta, GA) will further differentiate ibrutinib from any potential competitors."

Pharmacyclics closed at $55.01 on Thursday.

Latest Ratings for PCYC

Nov 2014Morgan StanleyMaintainsEqual-weight
Nov 2014JMP SecuritiesMaintainsMarket Outperform
Nov 2014NomuraMaintainsBuy

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (PCYC)

Around the Web, We're Loving...

Get Benzinga's Newsletters